OS Animal Health Plans Crowdfunding, Seeks USDA Path After 20% Two-Year Survival
OSTX•OS Animal Health's peer-reviewed Phase 2 trial found OST-HER2 plus radiation achieved 20% two-year survival versus 1% with radiation alone in frontline canine osteosarcoma (p=0.00995). The company will meet USDA in Q3 2026 for approval alignment and launch crowdfunding to broaden its shareholder base ahead of a U.S. exchange listing.
1. Phase 2 Trial Demonstrates Survival Benefit
OS Animal Health published peer-reviewed data showing OST-HER2 combined with palliative radiation delivered a 20% two-year survival rate in frontline canine osteosarcoma versus 1% with radiation alone (p=0.00995). The study enrolled 15 treated dogs and 83 controls, highlighting a significant efficacy signal for the immunotherapy candidate.
2. USDA Meeting for Conditional Approval
The company plans to request a meeting with the U.S. Department of Agriculture in the third quarter of 2026 to discuss a regulatory path for conditional licensure of OST-HER2 in canines. This step follows global alignment on manufacturing requirements and aims to secure pre-market approval for veterinary use.
3. Crowdfunding and Shareholder Expansion
To meet U.S. national exchange initial listing standards, OS Animal Health will initiate a crowdfunding campaign in Q3 2026 to broaden its shareholder base. This strategy complements the planned distribution of subsidiary shares to OS Therapies shareholders and supports the business’s go-public objectives.
